ImmunoCellular Therapeutics' ICT-107 Recognized As One Of Windhover's Top 10 Most Licensable Oncology Products
September 28, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that ICT-107 was recognized as one of Windhover's Top 10 licensable oncology products. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. ICT-107 is the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
ImmunoCellular was chosen by Campbell Alliance Business Development group using a variety of criteria, including mechanism of action, initial marketable indication and potential for follow-on indications to identify products and trends in the oncology space where license activity will most likely begin within the year.
"We are excited with the promise ICT-107 has demonstrated in patients with GBM, and are pleased that industry experts have recognized the potential of the drug candidate to attract partners to accelerate its develop," said Manish Singh, Ph.D. President and CEO of ImmunoCellular Therapeutics.
In ImmunoCellular's Phase I trial of ICT-107, the three-year overall survival is 55%, compared to 16% based on historical standard of care (SOC). The data from that trial shows that 38% of newly diagnosed patients who received ICT-107 continue to show no tumor recurrence after three years, compared to the historic disease-free survival rate of 6% with SOC. Out of these patients, 19% remain disease-free after more than four years.
The Phase I clinical study was conducted in 16 newly diagnosed glioblastoma patients, who received three injections of ICT-107 in addition to standard treatment with surgery, radiation and chemotherapy. The company has previously reported a two-year survival rate of 80.2% in study patients, which compares favorably to the historic median two-year survival rate of 26.5% with SOC alone. No serious adverse events have been reported and minor side effects have been limited to fatigue, skin rash and pruritis.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd.
Source: ImmunoCellular Therapeutics, Ltd.